TABLE 1.
Demographic and clinicopathologic characteristics of 785 patients with breast cancer.
| Parameters | N | SIRI 785 | N | SIRI 477 | N | SIRI 308 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n) | 785 | Low SIRI 484 | High SIRI 301 | χ2 | p value | Low SIRI 267 | High SIRI 210 | χ2 | p value | Low SIRI 217 | High SIRI 91 | χ2 | p value | ||
| Age (years) | 0.193 | 0.660 | 0.054 | 0.816 | 1.504 | 0.220 | |||||||||
| <47 | 386 (49.17%) | 235 (48.55%) | 151 (50.17%) | 230 (48.22%) | 130 (48.69%) | 100 (47.62%) | 156 (50.65%) | 105 (48.39%) | 51 (56.04%) | ||||||
| ≥47 | 399 (50.83%) | 249 (51.45%) | 150 (49.83%) | 247 (51.78%) | 137 (51.31%) | 110 (52.38%) | 152 (49.35%) | 112 (51.61%) | 40 (43.96%) | ||||||
| Marital status | 0.117 | 0.732 | 0.690 | 0.406 | 3.013 | 0.083 | |||||||||
| Married | 756 (96.31%) | 467 (96.49%) | 289 (96.01%) | 457 (95.81%) | 254 (95.13%) | 203 (96.67%) | 299 (97.08%) | 213 (98.16%) | 86 (94.51%) | ||||||
| Unmarried | 29 (3.69%) | 17 (3.51%) | 12 (3.99%) | 20 (4.19%) | 13 (4.87%) | 7 (3.33%) | 9 (2.92%) | 4 (1.84%) | 5 (5.49%) | ||||||
| Occupation | 3.276 | 0.194 | 0.133 | 0.936 | 7.681 | 0.022 | |||||||||
| Mental worker | 358 (45.61%) | 226 (46.69%) | 132 (43.85%) | 238 (49.90%) | 135 (50.56%) | 103 (49.05%) | 120 (38.96%) | 91 (41.94%) | 29 (31.87%) | ||||||
| Manual worker | 125 (15.92%) | 83 (17.15%) | 42 (13.95%) | 66 (13.84%) | 37 (13.86%) | 29 (13.81%) | 59 (19.16%) | 46 (21.20%) | 13 (14.29%) | ||||||
| Others | 302 (38.47%) | 175 (36.16%) | 127 (42.19%) | 173 (36.27%) | 95 (35.58%) | 78 (37.14%) | 129 (41.88%) | 80 (36.87%) | 49 (53.85%) | ||||||
| Weight (kg) | 1.014 | 0.314 | 0.677 | 0.411 | 0.465 | 0.495 | |||||||||
| <62.00 | 383 (48.79%) | 243 (50.21%) | 140 (46.51%) | 235 (49.27%) | 136 (50.94%) | 99 (47.14%) | 148 (48.05%) | 107 (49.31%) | 41 (45.05%) | ||||||
| ≥62.00 | 402 (51.21%) | 241 (49.79%) | 161 (53.49%) | 242 (50.73%) | 131 (49.06%) | 111 (52.86%) | 160 (51.95%) | 110 (50.69%) | 50 (54.95%) | ||||||
| Height (m) | 1.696 | 0.193 | 0.036 | 0.850 | 2.244 | 0.134 | |||||||||
| <1.60 | 337 (42.93%) | 199 (41.12%) | 138 (45.85%) | 218 (45.70%) | 121 (45.32%) | 97 (46.19%) | 119 (38.64%) | 78 (35.94%) | 41 (45.05%) | ||||||
| ≥1.60 | 448 (57.07%) | 285 (58.88%) | 163 (54.15%) | 259 (54.30%) | 146 (54.68%) | 113 (53.81%) | 189 (61.36%) | 139 (64.06%) | 50 (54.95%) | ||||||
| BMI | 4.801 | 0.028 | 2.674 | 0.102 | 3.186 | 0.074 | |||||||||
| <24.00 | 391 (49.81%) | 256 (52.89%) | 135 (44.85%) | 245 (51.36%) | 146 (54.68%) | 99 (47.14%) | 146 (47.40%) | 110 (50.69%) | 36 (39.56%) | ||||||
| ≥24.00 | 394 (50.19%) | 228 (47.11%) | 166 (55.15%) | 232 (48.64%) | 121 (45.32%) | 111 (52.86%) | 162 (52.60%) | 107 (49.31%) | 55 (60.44%) | ||||||
| Menarche age (year) | 1.076 | 0.300 | 0.484 | 0.487 | 0.246 | 0.620 | |||||||||
| <14 | 308 (39.24%) | 183 (37.81%) | 125 (41.53%) | 196 (41.09%) | 106 (39.70%) | 90 (42.86%) | 112 (36.36%) | 77 (35.48%) | 35 (38.46%) | ||||||
| ≥14 | 477 (60.76%) | 301 (62.19%) | 176 (58.47%) | 281 (58.91%) | 161 (60.30%) | 120 (57.14%) | 196 (63.64%) | 140 (64.52%) | 56 (61.54%) | ||||||
| Menopause | 1.119 | 0.290 | 2.674 | 0.102 | 0.083 | 0.773 | |||||||||
| No | 493 (62.80%) | 297 (61.36%) | 196 (65.12%) | 280 (58.70%) | 148 (55.43%) | 132 (62.86%) | 213 (69.16%) | 149 (68.66%) | 64 (70.33%) | ||||||
| Yes | 292 (37.20%) | 187 (38.64%) | 105 (34.88%) | 197 (41.30%) | 119 (44.57%) | 78 (37.14%) | 95 (30.84%) | 68 (31.34%) | 27 (29.67%) | ||||||
| ABO blood type | 2.449 | 0.654 | 4.406 | 0.354 | 2.856 | 0.582 | |||||||||
| A | 214 (27.26%) | 129 (26.65%) | 85 (28.24%) | 132 (27.67%) | 68 (25.47%) | 64 (30.48%) | 82 (26.62%) | 61 (28.11%) | 21 (23.08%) | ||||||
| B | 262 (33.38%) | 168 (34.71%) | 94 (31.23%) | 145 (30.40%) | 83 (31.09%) | 62 (29.52%) | 117 (37.99%) | 85 (39.17%) | 32 (35.16%) | ||||||
| O | 234 (29.81%) | 146 (30.17%) | 88 (29.24%) | 146 (30.61%) | 90 (33.71%) | 56 (26.67%) | 88 (28.57%) | 56 (25.81%) | 32 (35.16%) | ||||||
| AB | 75 (9.55%) | 41 (8.47%) | 34 (11.30%) | 54 (11.32%) | 26 (9.74%) | 28 (13.33%) | 21 (6.82%) | 15 (6.91%) | 6 (6.59%) | ||||||
| Tumor site | 0.049 | 0.824 | 1.404 | 0.236 | 2.417 | 0.120 | |||||||||
| Right | 369 (47.01%) | 226 (46.69%) | 143 (47.51%) | 233 (48.85%) | 124 (46.44%) | 109 (51.90%) | 136 (44.16%) | 102 (47.00%) | 34 (37.36%) | ||||||
| Left | 416 (52.99%) | 258 (53.31%) | 158 (52.49%) | 244 (51.15%) | 143 (53.56%) | 101 (48.10%) | 172 (55.84%) | 115 (53.00%) | 57 (62.64%) | ||||||
| Clinical T stage | 19.137 | 0.001 | 10.284 | 0.036 | 3.161 | 0.531 | |||||||||
| T1 | 168 (21.40%) | 113 (23.35%) | 68 (22.59%) | 65 (13.63%) | 43 (16.10%) | 22 (10.48%) | 103 (33.44%) | 70 (32.26%) | 33 (36.26%) | ||||||
| T2 | 413 (52.61%) | 269 (55.58%) | 132 (43.85%) | 226 (47.38%) | 133 (49.81%) | 93 (44.29%) | 187 (60.71%) | 136 (62.67%) | 51 (56.04%) | ||||||
| T3 | 131 (16.69%) | 71 (14.67%) | 59 (19.60%) | 115 (24.11%) | 62 (23.22%) | 53 (25.24%) | 16 (5.19%) | 9 (4.15%) | 7 (7.69%) | ||||||
| T4 | 73 (9.30%) | 31 (6.40%) | 42 (13.95%) | 71 (14.88%) | 29 (10.86%) | 42 (20.00%) | 2 (0.65%) | 2 (0.92%) | 0 (0.00%) | ||||||
| Clinical N stage | 14.841 | 0.005 | 0.665 | 0.956 | 5.613 | 0.230 | |||||||||
| N0 | 299 (38.09%) | 210 (43.39%) | 90 (29.90%) | 73 (15.30%) | 44 (16.48%) | 29 (13.81%) | 226 (73.38%) | 166 (76.50%) | 60 (65.93%) | ||||||
| N1 | 233 (29.68%) | 135 (27.89%) | 97 (32.23%) | 164 (34.38%) | 90 (33.71%) | 74 (35.24%) | 69 (22.40%) | 45 (20.74%) | 24 (26.37%) | ||||||
| N2 | 160 (20.38%) | 88 (18.18%) | 72 (23.92%) | 151 (31.66%) | 84 (31.46%) | 67 (31.90%) | 9 (2.92%) | 4 (1.84%) | 5 (5.49%) | ||||||
| N3 | 93 (11.85%) | 51 (10.54%) | 42 (13.95%) | 89 (18.66%) | 49 (18.35%) | 40 (19.05%) | 4 (1.30%) | 2 (0.92%) | 2 (2.20%) | ||||||
| Clinical TNM stage | 12.114 | 0.002 | 1.930 | 0.381 | 0.555 | 0.758 | |||||||||
| I | 92 (11.72%) | 66 (13.64%) | 26 (8.64%) | 14 (2.94%) | 10 (3.75%) | 4 (1.90%) | 78 (25.32%) | 56 (25.81%) | 22 (24.18%) | ||||||
| II | 382 (48.66%) | 248 (51.24%) | 134 (44.52%) | 168 (35.22%) | 97 (36.33%) | 71 (33.81%) | 214 (69.48%) | 151 (69.59%) | 63 (69.23%) | ||||||
| III | 311 (39.62%) | 170 (35.12%) | 141 (46.84%) | 295 (61.84%) | 160 (59.93%) | 135 (64.29%) | 16 (5.19%) | 10 (4.61%) | 6 (6.59%) | ||||||
| Neoadjuvant Chemotherapy | |||||||||||||||
| Chemotherapy regimen | 46.320 | <0.0001 | |||||||||||||
| EC/ECF | 28 (5.87%) | 21 (7.87%) | 7 (3.33%) | ||||||||||||
| CT/ECT | 27 (5.66%) | 21 (7.87%) | 6 (2.86%) | ||||||||||||
| ET | 223 (46.75%) | 131 (49.06%) | 92 (43.81%) | ||||||||||||
| TP | 141 (29.56%) | 61 (22.85%) | 80 (38.10%) | ||||||||||||
| Others | 58 (12.16%) | 33 (12.36%) | 25 (11.90%) | ||||||||||||
| Chemotherapy times | 3.407 | 0.065 | |||||||||||||
| <6 | 134 (28.09%) | 84 (31.46%) | 50 (23.81%) | ||||||||||||
| ≥6 | 343 (71.91%) | 183 (68.54%) | 160 (76.19%) | ||||||||||||
| Response | 1.326 | 0.857 | |||||||||||||
| CR | 7 (1.47%) | 6 (2.25%) | 1 (0.48%) | ||||||||||||
| PR | 312 (65.41%) | 169 (63.30%) | 143 (68.10%) | ||||||||||||
| SD | 151 (31.66%) | 86 (32.21%) | 65 (30.95%) | ||||||||||||
| PD | 7 (1.47%) | 6 (2.25%) | 1 (0.48%) | ||||||||||||
| Miller and Payne grade | 9.371 | 0.053 | |||||||||||||
| 1 | 22 (4.61%) | 11 (4.12%) | 11 (5.24%) | ||||||||||||
| 2 | 126 (26.42%) | 70 (26.22%) | 56 (26.67%) | ||||||||||||
| 3 | 177 (37.11%) | 112 (41.95%) | 65 (30.95%) | ||||||||||||
| 4 | 62 (13.00%) | 26 (9.74%) | 36 (17.14%) | ||||||||||||
| 5 | 90 (18.87%) | 48 (17.98%) | 42 (20.00%) | ||||||||||||
| Pathological response | 0.024 | 0.876 | |||||||||||||
| pCR | 72 (15.09%) | 40 (14.98%) | 32 (15.24%) | ||||||||||||
| non-pCR | 405 (84.91%) | 229 (85.77%) | 176 (83.81%) | ||||||||||||
| Post-chemotherapy regimen | 16.590 | 0.005 | 6.457 | 0.264 | 13.250 | 0.021 | |||||||||
| EC/ECF | 125 (15.92%) | 88 (18.18%) | 37 (12.29%) | 43 (9.01%) | 25 (9.36%) | 18 (8.57%) | 82 (26.62%) | 63 (29.03%) | 19 (20.88%) | ||||||
| CT/ECT | 125 (15.92%) | 75 (15.50%) | 50 (16.61%) | 30 (6.29%) | 20 (7.49%) | 10 (4.76%) | 95 (30.84%) | 55 (25.35%) | 40 (43.96%) | ||||||
| ET | 97 (12.36%) | 71 (14.67%) | 26 (8.64%) | 37 (7.76%) | 25 (9.36%) | 12 (5.71%) | 60 (19.48%) | 46 (21.20%) | 14 (15.38%) | ||||||
| TP | 61 (7.77%) | 37 (7.64%) | 24 (7.97%) | 39 (8.18%) | 23 (8.61%) | 16 (7.62%) | 22 (7.14%) | 14 (6.45%) | 8 (8.79%) | ||||||
| Others | 108 (13.76%) | 68 (14.05%) | 40 (13.29%) | 81 (16.98%) | 48 (17.98%) | 33 (15.71%) | 27 (8.77%) | 20 (9.22%) | 7 (7.69%) | ||||||
| NO | 269 (34.27%) | 145 (29.96%) | 124 (41.20%) | 247(51.78%) | 126 (47.19%) | 121 (57.62%) | 22 (7.14%) | 19 (8.76%) | 3 (3.30%) | ||||||
| Type of surgery | 0.082 | 0.775 | 0.037 | 0.848 | 0.654 | 0.419 | |||||||||
| Mastectomy | 606 (77.20%) | 372 (76.86%) | 234 (77.74%) | 406 (85.12%) | 228 (85.39%) | 178 (84.76%) | 200 (64.94%) | 144 (66.36%) | 56 (61.54%) | ||||||
| Breast-conserving surgery | 179 (22.80%) | 112 (23.14%) | 67 (22.26%) | 71 (14.88%) | 39 (14.61%) | 32 (15.24%) | 108 (35.06%) | 73 (33.64%) | 35 (38.46%) | ||||||
| Tumor size (cm) | 0.785 | 0.675 | 0.512 | 0.774 | 0.016 | 0.992 | |||||||||
| ≤2 cm | 437 (55.67%) | 267 (55.17%) | 170 (56.48%) | 263 (55.14%) | 144 (53.93%) | 119 (56.67%) | 174 (56.49%) | 123 (56.68%) | 51 (56.04%) | ||||||
| >2 and <5 cm | 299 (38.09%) | 189 (39.05%) | 110 (36.54%) | 172 (36.06%) | 100 (37.45%) | 72 (34.29%) | 127 (41.23%) | 89 (41.01%) | 38 (41.76%) | ||||||
| ≥5 cm | 49 (6.24%) | 28 (5.79%) | 21 (6.98%) | 42 (8.81%) | 23 (8.61%) | 19 (9.05%) | 7 (2.27%) | 5 (2.30%) | 2 (2.20%) | ||||||
| Histologic type | 1.481 | 0.477 | 0.906 | 0.636 | 3.556 | 0.169 | |||||||||
| Ductal | 758 (96.56%) | 470 (97.11%) | 288 (95.68%) | 461 (96.65%) | 258 (96.63%) | 203 (96.67%) | 297 (96.43%) | 212 (97.70%) | 85 (93.41%) | ||||||
| Lobular | 13 (1.66%) | 6 (1.24%) | 7 (2.33%) | 7 (1.47%) | 3 (1.12%) | 4 (1.90%) | 6 (1.95%) | 3 (1.38%) | 3 (3.30%) | ||||||
| Others | 14 (1.78%) | 8 (1.65%) | 6 (1.99%) | 9 (1.89%) | 6 (2.25%) | 3 (1.43%) | 5 (1.62%) | 2 (0.92%) | 3 (3.30%) | ||||||
| Histologic grade | 3.881 | 0.144 | 3.327 | 0.190 | 5.327 | 0.070 | |||||||||
| I | 133 (16.94%) | 76 (15.70%) | 57 (18.94%) | 108 (22.64%) | 54 (20.22%) | 54 (25.71%) | 25 (8.12%) | 22 (10.14%) | 3 (3.30%) | ||||||
| II | 431 (54.90%) | 279 (57.64%) | 152 (50.50%) | 244 (51.15%) | 146 (54.68%) | 98 (46.67%) | 187 (60.71%) | 133 (61.29%) | 54 (59.34%) | ||||||
| III | 221 (28.15%) | 129 (26.65%) | 92 (30.56%) | 125 (26.21%) | 67 (25.09%) | 58 (27.62%) | 96 (31.17%) | 62 (28.57%) | 34 (37.36%) | ||||||
| Pathological TNM classification | |||||||||||||||
| Pathological T stage | 4.021 | 0.403 | 2.050 | 0.727 | 1.824 | 0.768 | |||||||||
| Tis/T0 | 92 (11.72%) | 50 (10.33%) | 42 (13.95%) | 88 (18.45%) | 46 (17.23%) | 42 (20.00%) | 4 (1.30%) | 4 (1.84%) | 0 (0.00%) | ||||||
| T1 | 302 (38.47%) | 187 (38.64%) | 115 (38.21%) | 190 (39.83%) | 108 (40.45%) | 82 (39.05%) | 112 (36.36%) | 79 (36.41%) | 33 (36.26%) | ||||||
| T2 | 326 (41.53%) | 208 (42.98%) | 118 (39.20%) | 149 (31.24%) | 85 (31.84%) | 64 (30.48%) | 177 (57.47%) | 123 (56.68%) | 54 (59.34%) | ||||||
| T3 | 45 (5.73%) | 29 (5.99%) | 16 (5.32%) | 34 (7.13%) | 21 (7.87%) | 13 (6.19%) | 11 (3.57%) | 8 (3.69%) | 3 (3.30%) | ||||||
| T4 | 20 (2.55%) | 10 (2.07%) | 10 (3.32%) | 16 (3.35%) | 7 (2.62%) | 9 (4.29%) | 4 (1.30%) | 3 (1.38%) | 1 (1.10%) | ||||||
| Pathological N stage | 2.054 | 0.726 | 1.523 | 0.823 | 1.628 | 0.804 | |||||||||
| N0 | 326 (41.53%) | 201 (41.53%) | 125 (41.53%) | 176 (36.90%) | 96 (35.96%) | 80 (38.10%) | 150 (48.70%) | 105 (48.39%) | 45 (49.45%) | ||||||
| N1 | 175 (22.29%) | 115 (23.76%) | 60 (19.93%) | 101 (21.17%) | 62 (23.22%) | 39 (18.57%) | 74 (24.03%) | 53 (24.42%) | 21 (23.08%) | ||||||
| N2 | 122 (15.54%) | 71 (14.67%) | 51 (16.94%) | 77 (16.14%) | 42 (15.73%) | 35 (16.67%) | 45 (14.61%) | 29 (13.36%) | 16 (17.58%) | ||||||
| N3 | 162 (20.64%) | 97 (20.04%) | 65 (21.59%) | 123 (25.79%) | 67 (25.09%) | 56 (26.67%) | 39 (12.66%) | 30 (13.82%) | 9 (9.89%) | ||||||
| Pathological TNM stage | 2.384 | 0.666 | 1.795 | 0.773 | 1.621 | 0.805 | |||||||||
| Tis/T0 | 74 (9.43%) | 43 (8.88%) | 31 (10.30%) | 71 (14.88%) | 40 (14.98%) | 31 (14.76%) | 3 (0.97%) | 3 (1.38%) | 0 (0.00%) | ||||||
| I | 157 (20.00%) | 96 (19.83%) | 61 (20.27%) | 83 (17.40%) | 44 (16.48%) | 39 (18.57%) | 74 (24.03%) | 52 (23.96%) | 22 (24.18%) | ||||||
| II | 262 (33.38%) | 171 (35.33%) | 91 (30.23%) | 118 (24.74%) | 72 (26.97%) | 46 (21.90%) | 144 (46.75%) | 99 (45.62%) | 45 (49.45%) | ||||||
| III | 292 (37.20%) | 174 (35.95%) | 118 (39.20%) | 205 (42.98%) | 111 (41.57%) | 94 (44.76%) | 87 (28.25%) | 63 (29.03%) | 24 (26.37%) | ||||||
| Total lymph nodes | 0.204 | 0.652 | 2.866 | 0.091 | 0.047 | 0.829 | |||||||||
| <21 | 391 (49.81%) | 238 (49.17%) | 153 (50.83%) | 202 (42.35%) | 104 (38.95%) | 98 (46.67%) | 189 (61.36%) | 134 (61.75%) | 55 (60.44%) | ||||||
| ≥21 | 394 (50.19%) | 246 (50.83%) | 148 (49.17%) | 275 (57.65%) | 163 (61.05%) | 112 (53.33%) | 119 (38.64%) | 83 (38.25%) | 36 (39.56%) | ||||||
| Positive lymph nodes | 0.103 | 0.749 | 0.175 | 0.676 | 0.109 | 0.742 | |||||||||
| <1 | 329 (41.91%) | 205 (42.36%) | 124 (41.20%) | 179 (37.53%) | 98 (36.70%) | 81 (38.57%) | 150 (48.70%) | 107 (49.31%) | 43 (47.25%) | ||||||
| ≥1 | 456 (58.09%) | 279 (57.64%) | 177 (58.80%) | 298 (62.47%) | 169 (63.30%) | 129 (61.43%) | 158 (51.30%) | 110 (50.69%) | 48 (52.75%) | ||||||
| Postoperative complications | 0.002 | 0.968 | 0.017 | 0.898 | 0.375 | 0.540 | |||||||||
| No | 728 (92.74%) | 449 (92.77%) | 279 (92.69%) | 449 (94.13%) | 251 (94.01%) | 198 (94.29%) | 279 (90.58%) | 198 (91.24%) | 81 (89.01%) | ||||||
| Yes | 57 (7.26%) | 35 (7.23%) | 22 (7.31%) | 28 (5.87%) | 16 (5.99%) | 12 (5.71%) | 29 (9.42%) | 19 (8.76%) | 10 (10.99%) | ||||||
| Postoperative chemotherapy | 10.404 | 0.001 | 5.120 | 0.024 | 2.881 | 0.090 | |||||||||
| No | 269 (34.27%) | 145 (29.96%) | 124 (41.20%) | 247 (51.78%) | 126 (47.19%) | 121 (57.62%) | 22 (7.14%) | 19 (8.76%) | 3 (3.30%) | ||||||
| Yes | 516 (65.73%) | 339 (70.04%) | 177 (58.80%) | 230 (48.22%) | 141 (52.81%) | 89 (42.38%) | 286 (92.86%) | 198 (91.24%) | 88 (96.70%) | ||||||
| Postoperative chemotherapy times | 13.066 | 0.0003 | 5.320 | 0.021 | 1.473 | 0.225 | |||||||||
| <4 | 374 (47.64%) | 206 (42.56%) | 168 (55.81%) | 340 (71.28%) | 179 (67.04%) | 161 (76.67%) | 34 (11.04%) | 27 (12.44%) | 7 (7.69%) | ||||||
| ≥4 | 411 (52.36%) | 278 (57.44%) | 133 (44.19%) | 137 (28.72%) | 88 (32.96%) | 49 (23.33%) | 274 (88.96%) | 190 (87.56%) | 84 (92.31%) | ||||||
| Postoperative radiotherapy | 0.496 | 0.481 | 0.118 | 0.732 | 2.750 | 0.097 | |||||||||
| No | 196 (24.97%) | 125 (25.83%) | 71 (23.59%) | 119 (24.95%) | 65 (24.34%) | 54 (25.71%) | 77 (25.00%) | 60 (27.65%) | 17 (18.68%) | ||||||
| Yes | 589 (75.03%) | 359 (74.17%) | 230 (76.41%) | 358 (75.05%) | 202 (75.66%) | 156 (74.29%) | 231 (75.00%) | 157 (72.35%) | 74 (81.32%) | ||||||
| Postoperative endocrine therapy | 1.927 | 0.165 | 0.059 | 0.808 | 1.563 | 0.211 | |||||||||
| No | 302 (38.47%) | 177 (36.57%) | 125 (41.53%) | 206 (43.19%) | 114 (42.70%) | 92 (43.81%) | 96 (31.17%) | 63 (29.03%) | 33 (36.26%) | ||||||
| Yes | 483 (61.53%) | 307 (63.43%) | 176 (58.47%) | 271 (56.81%) | 153 (57.30%) | 118 (56.19%) | 212 (68.83%) | 154 (70.97%) | 58 (63.74%) | ||||||
| Postoperative targeted therapy | 9.697 | 0.002 | 4.153 | 0.042 | 2.753 | 0.097 | |||||||||
| No | 583 (74.27%) | 378 (78.10%) | 205 (68.11%) | 332 (69.60%) | 196 (73.41%) | 136 (64.76%) | 251 (81.49%) | 182 (83.87%) | 69 (75.82%) | ||||||
| Yes | 202 (25.73%) | 106 (21.90%) | 96 (31.89%) | 145 (30.40%) | 71 (26.59%) | 74 (35.24%) | 57 (18.51%) | 35 (16.13%) | 22 (24.18%) | ||||||